Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients
Status:
Completed
Trial end date:
2020-06-23
Target enrollment:
Participant gender:
Summary
Aim of this trial is to assess the efficacy of new anti-CD20 antibody (GA101) in association
with DHAP as induction therapy before high dose chemotherapy BEAM with ASCT in patients with
relapsed/refractory DLBCL.